Abstract 198TiP
Background
Gastric cancer (GC) is the fourth leading cause of cancer death worldwide, with disproportionate incidence and mortality rates reported for people from Eastern Asia. Fluorouracil (5-FU), folinic acid, and oxaliplatin (mFOLFOX6) is an accepted chemotherapy for first-line treatment of locally advanced/metastatic GC/GEJ. Recently, Claudin (CLDN)18.2 has emerged as a promising targetable biomarker. In healthy tissue, CLDN18.2 is confined to gastric mucosa tight junctions. Upon malignant transformation, cell polarity perturbations lead to exposure of CLDN18.2 on the cell surface. Zolbetuximab is a chimeric IgG1 monoclonal antibody that specifically binds to CLDN18.2 and mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. In a randomized phase 2 study (NCT01630083), patients with CLDN18.2+ advanced GC/GEJ treated with zolbetuximab + epirubicin, oxaliplatin, and capecitabine (EOX) showed prolonged survival compared with EOX alone.
Trial design
This phase 3, double-blind, placebo-controlled study (NCT03504397) will enroll ∼550 adult patients from global sites, Japan, Republic of Korea, and Taiwan. Patients with CLDN18.2+/HER2– locally advanced unresectable or metastatic GC or GEJ who have not been previously treated with chemotherapy will be eligible. Patients will be randomized 1:1 to receive zolbetuximab + mFOLFOX6 or placebo + mFOLFOX6. Zolbetuximab will be administered by IV infusion as an 800-mg/m2 loading dose followed by 600 mg/m2 Q3W and mFOLFOX6 Q2W. During screening, central testing of tumor tissue will determine CLDN18.2 and HER2 status (if unknown); patients will be considered CLDN18.2+ if ≥ 75% of tumor cells demonstrate moderate-to-strong IHC staining. The primary objective is to compare the progression-free survival between treatment arms. The key secondary efficacy endpoint is overall survival. Objective response rate, duration of response, safety/tolerability, PK, and immunogenicity of zolbetuximab are other secondary endpoints.
Clinical trial identification
NCT03504397.
Legal entity responsible for the study
Astellas Pharma US, Inc.
Funding
Astellas Pharma US, Inc.
Disclosure
K. Yamaguchi: Research grant/Funding (self): Astellas Pharma, Inc.; Research grant/Funding (self): Eli Lilly; Research grant/Funding (self): Taiho Pharmaceutical; Research grant/Funding (self): Chugai Pharmaceutical; Research grant/Funding (self): Merck Serono; Research grant/Funding (self): Takeda; Research grant/Funding (self): Daiichi-Sankyo; Research grant/Funding (self): Ono Pharmaceutical; Research grant/Funding (self): Bristol-Myers Squibb; Research grant/Funding (self): Bayer; Research grant/Funding (self): Yakurt Honsha; Research grant/Funding (self): Dainippon Sumitomo; Research grant/Funding (self): Boehringer Ingelheim; Research grant/Funding (self): Gilead. K. Shitara: Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Takeda; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self): Novartis; Honoraria (self): AbbVie; Honoraria (self): Yakult; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Chugai Pharma; Advisory / Consultancy, Research grant / Funding (institution): MSD; Research grant / Funding (institution): Medi Science. S-E. Al-Batran: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: SERVIER; Speaker Bureau / Expert testimony: Nordic Bioscience; Research grant / Funding (institution): Hospira; Research grant / Funding (institution): Medac; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Roche Pharma AG; Research grant / Funding (institution): Vifor Pharma. Y-J. Bang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Merck Serano; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Taiho; Advisory / Consultancy, Research grant / Funding (institution): Daiich-Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): BeiGene; Advisory / Consultancy, Research grant / Funding (institution): GreenCross; Advisory / Consultancy, Research grant / Funding (institution): Samyang Biopharm; Advisory / Consultancy: Hanmi; Advisory / Consultancy, Research grant / Funding (institution): Genexine; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): MacroGenics. D. Catenacci: Honoraria (self): Astellas; Honoraria (self): Merck; Honoraria (self): BMS; Honoraria (self): Lilly; Honoraria (self): Gristone; Honoraria (self): Taiho; Honoraria (self): Genetech/Roche; Honoraria (self): Daichii Sankyo . P. Enzinger: Advisory / Consultancy: Merck; Advisory / Consultancy: Astellas; Advisory / Consultancy: Celgene; Advisory / Consultancy: Lilly; Advisory / Consultancy: Loxo; Advisory / Consultancy: Taiho. D. Ilson: Honoraria (self), Advisory / Consultancy: Astellas. S. Kim: Advisory / Consultancy: Astellas. F. Lordick: Advisory / Consultancy: Astellas; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: AstraZeneca. E. Van Cutsem: Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Ipsen; Advisory / Consultancy: Incyte; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Advisory / Consultancy, Research grant / Funding (institution): Merck KGaA; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Servier . A. Arozullah: Full / Part-time employment: Astellas. J. Wook Park: Full / Part-time employment: Astellas Pharma Global Development Inc. J. Ajani: Advisory / Consultancy, Research grant / Funding (institution): Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract